Transgene: first patient in phase II study

(CercleFinance.com) - Transgene announced on Monday the inclusion of the first patient in the phase II part of its phase I/II study evaluating its therapeutic vaccine candidate TG4050 in the adjuvant treatment of head and neck cancer, in line with the initially envisaged timetable.


In a press release, the biotech indicates that patient selection and inclusion have started, with the aim of randomizing around 80 patients in the overall international study.

Inclusion of the last patient for the phase II portion is expected in the fourth quarter of 2025.

TG4050, an individualized immunotherapy designed from each patient's tumor, had shown promising results in phase I, with all treated patients in remission and without recurrence.

The stock gained 5% on Monday on the Paris Bourse following these announcements.

Copyright (c) 2024 CercleFinance.com. All rights reserved.